• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Senti Biosciences Inc.

    5/15/25 4:43:33 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SNTI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Senti Biosciences, Inc.

    (Name of Issuer)


    Common stock, par value $0.0001 per share

    (Title of Class of Securities)


    81726A209

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    81726A209


    1Names of Reporting Persons

    NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    502,500.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    502,500.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    502,500.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.9 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Senti Biosciences, Inc.
    (b)Address of issuer's principal executive offices:

    2 Corporate Drive, First Floor South San Francisco, CA, 94080
    Item 2. 
    (a)Name of person filing:

    NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP ("Nantahala")
    (b)Address or principal business office or, if none, residence:

    130 Main St. 2nd Floor, New Canaan, CT 06840
    (c)Citizenship:

    Nantahala is a Massachusetts limited partnership.
    (d)Title of class of securities:

    Common stock, par value $0.0001 per share
    (e)CUSIP No.:

    81726A209
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of March 31, 2025, Nantahala may be deemed to be the beneficial owner of 502,500 Shares. The 502,500 Shares includes 301,500 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of warrants.
    (b)Percent of class:

    As of March 31, 2025, each of the Reporting Persons may be deemed to be the beneficial owner of 1.9% of the total number of Shares outstanding, based on 26,004,266 shares outstanding.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    502,500

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    502,500

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP
     
    Signature:/s/ Taki Vasilakis
    Name/Title:Taki Vasilakis / Chief Compliance Officer Nantahala Capital Management, LLC
    Date:05/15/2025
     
    Signature:/s/ Wilmot B. Harkey
    Name/Title:Wilmot B. Harkey / Manager Nantahala Capital Management, LLC
    Date:05/15/2025
     
    Signature:/s/ Daniel Mack
    Name/Title:Daniel Mack / Manager Nantahala Capital Management, LLC
    Date:05/15/2025
    Get the next $SNTI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNTI

    DatePrice TargetRatingAnalyst
    6/6/2025$5.00Buy
    Laidlaw
    10/7/2022$7.50Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SNTI
    SEC Filings

    View All

    SEC Form 10-Q filed by Senti Biosciences Inc.

    10-Q - Senti Biosciences, Inc. (0001854270) (Filer)

    8/7/25 8:09:33 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Senti Biosciences, Inc. (0001854270) (Filer)

    8/7/25 8:06:35 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Senti Biosciences, Inc. (0001854270) (Filer)

    7/18/25 8:56:49 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Senti Bio with a new price target

    Laidlaw initiated coverage of Senti Bio with a rating of Buy and set a new price target of $5.00

    6/6/25 8:36:59 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley initiated coverage on Senti Bio with a new price target

    Morgan Stanley initiated coverage of Senti Bio with a rating of Equal-Weight and set a new price target of $7.50

    10/7/22 7:14:34 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Baum Bryan Daniel

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    7/21/25 5:56:55 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Baum Bryan Daniel

    3 - Senti Biosciences, Inc. (0001854270) (Issuer)

    7/21/25 5:55:39 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Collins James J.

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    6/27/25 7:55:15 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

    SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date/Time: Tuesday, August 19, 2025 at 2:20 PM ET Presenter: Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder and Chief Executive OfficerRegistration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform commit

    8/14/25 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio Participates in Virtual Investor "What This Means" Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

    Access the "What This Means" segment here SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor "What This Means" segment. For the segment, Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, discussed the Company's recently announced recommended Phase 2 dose selection for its potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell t

    8/12/25 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

    SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the second quarter of 2025 and provided a summary of recent pipeline and corporate highlights. "Our team has continued to advance SENTI-202's clinical development. We have now completed dose finding and have confirmed the recommended Phase 2 dose (RP2D), which is an important step in our Phase 1 study. We are currently in the dose expansion phase, enrolling additional patients with relapsed/refractory AML

    8/7/25 8:05:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Leadership Updates

    Live Leadership Updates

    View All

    Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

    Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development Vast experience in technology licensing, correlation from "bench to bedside" and back and execution of scientific strategy SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the appointment of James B. Trager, Ph.D. to its Scientific Advisor

    4/10/25 8:45:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

    SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    12/4/24 7:08:03 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Senti Biosciences Inc.

    SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)

    2/14/23 12:38:17 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Senti Biosciences Inc. (Amendment)

    SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)

    2/14/23 11:52:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Financials

    Live finance-specific insights

    View All

    Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

    SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date/Time: Tuesday, August 19, 2025 at 2:20 PM ET Presenter: Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder and Chief Executive OfficerRegistration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform commit

    8/14/25 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio Participates in Virtual Investor "What This Means" Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

    Access the "What This Means" segment here SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor "What This Means" segment. For the segment, Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, discussed the Company's recently announced recommended Phase 2 dose selection for its potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell t

    8/12/25 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

    SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the second quarter of 2025 and provided a summary of recent pipeline and corporate highlights. "Our team has continued to advance SENTI-202's clinical development. We have now completed dose finding and have confirmed the recommended Phase 2 dose (RP2D), which is an important step in our Phase 1 study. We are currently in the dose expansion phase, enrolling additional patients with relapsed/refractory AML

    8/7/25 8:05:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care